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Hindlimb suspension/reloadingMuscle wasting impairs physical performance, increases mortality and reduces medical intervention efﬁcacy in
chronic diseases and cancer. Developing proﬁcient intervention strategies requires improved understanding of
the molecular mechanisms governing muscle mass wasting and recovery. Involvement of muscle protein- and
myonuclear turnover during recovery from muscle atrophy has received limited attention. The insulin-like
growth factor (IGF)-I signaling pathway has been implicated inmusclemass regulation. As glycogen synthase ki-
nase 3 (GSK-3) is inhibited by IGF-I signaling, we hypothesized that muscle-speciﬁc GSK-3β deletion facilitates
the recovery of disuse-atrophied skeletal muscle. Wild-type mice and mice lacking muscle GSK-3β (MGSK-3β
KO) were subjected to a hindlimb suspension model of reversible disuse-induced muscle atrophy and followed
during recovery. Indices of muscle mass, protein synthesis and proteolysis, and post-natal myogenesis which
contribute to myonuclear accretion, were monitored during the reloading of atrophied muscle. Early muscle
mass recovery occurred more rapidly in MGSK-3β KO muscle. Reloading-associated changes in muscle protein
turnoverwere not affected byGSK-3β ablation. However, coherent effectswere observed in the extent and kinet-
ics of satellite cell activation, proliferation andmyogenic differentiation observed during reloading, suggestive of
increased myonuclear accretion in regenerating skeletal muscle lacking GSK-3β. This study demonstrates that
musclemass recovery and post-natal myogenesis from disuse-atrophy are accelerated in the absence of GSK-3β.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Chronic diseases, like congestive heart failure [1], rheumatoid arthri-
tis [2,3], chronic renal failure, AIDS [4], chronic obstructive pulmonary
disease (COPD) [5,6] and cancer [7,8] are associated with muscle
wasting. Muscle wasting impairs physical performance, increases mor-
tality and reduces efﬁcacy ofmedical intervention [9]. Currently, muscle
mass maintenance is an unmet-medical-need, which should be inte-
grated in the management of chronic diseases and cancer. Developing
proﬁcient intervention strategies requires improved understanding of
the molecular mechanisms governing muscle atrophy, hypertrophy, as
well as muscle mass recovery-associated muscle regeneration. These
mechanisms are regulated by balancing muscle protein synthesis and
degradation, and potentially myonuclear loss and accretion, referred
to as muscle protein-, and myonuclear turnover, respectively [10]. In-
volvement of these processes inmusclemass recovery followingmuscle
atrophy has received limited attention.
Muscle protein synthesis can be initiated through insulin-like growth
factor-I (IGF-I)-mediated activation of the Phosphatidylinositol-4,5-edicine, PO Box 5800, 6202 AZ
+31 43 387 5051.
.J. Langen).bisphosphate 3-kinase (PI-3K) signaling cascade leading to the
phosphorylation of Akt/PKB at Thr308/Ser473 [11–13]. Activated Akt
can subsequently phosphorylate both the mammalian target of
rapamycin (mTOR)–raptor complex 1 (mTORC1) [14,15] and the two
isoforms of GSK-3 [16,17], thereby initiatingmRNA translation resulting
in increased protein synthesis [18,19]. More speciﬁcally, activated
mTOR, when phosphorylated at Ser2448, phosphorylates p70-S6K1 at
Thr389 to stimulate translation capacity and hyper-phosphorylates
eIF4E binding protein 1 (4E-BP1) to inhibit the suppression of transla-
tion initiation [15,20–22]. In addition, Akt phosphorylation of GSK-3β
at Ser9 and GSK-3α at Ser21 suppresses GSK-3 function including its in-
hibitory phosphorylation of eIF2Bε at Ser540 [23,24], which allows
eIF2Bε to interact with the eIF2-complex and facilitates mRNA transla-
tion initiation [25,26]. Muscle proteolysis involves several proteolytic
systems, including the ubiquitin (Ub) 26S-proteasome system (UPS)
and the autophagy–lysosomal pathway (ALP) [10,27,28]. The UPS en-
tails selective proteolysis through the multi-ubiquitination of marked
proteins by rate-limiting E3 ubiquitin ligases [29], which results in the
degradation of the tagged proteins by the 26S-proteasome [30]. The
E3 ligases muscle-speciﬁc atrogin-1/muscle atrophy F-box (MAFbx)
(hereafter termed atrogin-1) and muscle-speciﬁc RING ﬁnger protein
1 (MuRF1) are upregulated under atrophic conditions [31,32] and regu-
late the proteolysis of myoﬁbrillar proteins, muscle-speciﬁc enzymes
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lived proteins and dysfunctional organelles through autophagosome
formation, which is initiated or aided by proteins like LC3, Gabarapl1
[37] and BNIP3 [38], whose presence is increased in atrophying muscle
[37,39,40].
Quiescent satellite cells, located between the skeletal muscle base-
ment and sarcolemmal membranes [41], are activated in response to
muscle injury or exercise stimulation leading to muscle recovery
[42–44]. The loss of myonuclei, and conversely activation and prolifera-
tion of satellite cells have been correlated to muscle atrophy and
growth, respectively [45–49], implying a role for post-natal myogenesis
and myonuclear accretion during muscle regeneration. Satellite cell ac-
tivation results in increased PAX7 expression [50–52], and cell prolifer-
ation characterized by increased expression of Cyclin D1, PCNA or
increased protein content of Ki-67 [53,54]. The resulting daughter myo-
blasts committed to muscle-speciﬁc differentiation fuse with existing
myoﬁbers [55], which are in part facilitated through cell–cell interaction
sites containingmuscle (M)-cadherin [56–58]. Myogenic differentiation
includes muscle-speciﬁc gene expression regulated by muscle regulato-
ry factors (MRFs), including Myf5, MyoD and Myogenin [59,60].
Altered expression of Mechano Growth Factor (MGF), a splice vari-
ant of IGF-I [61] accompanies local muscle repair, maintenance and
remodeling [62,63]. Moreover, both muscle protein turnover and
myonuclear turnover are subject to regulation by IGF-I signaling. Pro-
tein synthesis and muscle-speciﬁc gene expression can be stimulated
by IGF-I [64–66], whereas muscle proteolysis is suppressed by IGF-I
[14,67]. In addition, muscle-speciﬁc expression of IGF-I promotes
muscle regeneration [68], and IGF-I signaling stimulates both the prolif-
erative and differentiation potential of myoblasts [69–71]. Akt has been
identiﬁed as a signaling molecule that coordinates IGF-I-mediated
changes inmuscle protein synthesis and degradation, but the regulation
of myonuclear turnover by Akt is less well understood [72–74]. Ample
evidence suggests an important role of the Akt substrate GSK-3 in
muscle protein turnover, including muscle proteolysis during muscle
atrophy [75–77], as well as myogenic differentiation and muscle regen-
eration [65,78,79]. Importantly, whereas GSK3α andGSK3β operate in a
redundant manner in various cellular processes, previous studies
suggest that muscle proteolysis and myogenic differentiation may be
under unique control of GSK3β [75,79]. We therefore proposed a regu-
latory role of GSK-3β in skeletal muscle mass maintenance through its
involvement in both protein and myonuclear turnover balances [17].
In the current study, we hypothesized that muscle-speciﬁc deletion
of GSK-3β facilitates disuse-atrophied muscle mass recovery by stimu-
lating signaling associated with net protein accretion and post-natal
myogenesis. As inactivity is an important determinant of muscle atro-
phy associated with chronic disease and cancer [80], a model of revers-
ible, hindlimb suspension (HS)-induced muscle atrophy was deployed
to address this hypothesis. Wild-type Ctrl (WT) and muscle-speciﬁc
(M)GSK-3β KO mice were subjected to HS and subsequent reloading
(RL), and indices ofmusclemass, protein synthesis, proteolysis signaling
and myonuclear accretion were monitored during reloading-induced
muscle mass recovery.
2. Materials and methods
2.1. Animals
The animal study described here was approved by the Institutional
Animal Care Committee of Maastricht University (DEC-2009-074).
Male skeletal muscle-speciﬁc (M)GSK-3β KO animals on a C57/Bl6
background were generated by breeding GSK-3βﬂ/ﬂ MLC1f-Cre+/−
(MGSK-3β KO) with GSK-3βﬂ/ﬂ MLC1f-Cre−/− (Wild-type Ctrl/WT)
mice [81]. Double Cre-negative litter mates served as ‘wild type’ (WT)
controls. At the start of the experiment mice were 12.9 ± 1.1 weeks
old (young adults) and weighed 27.7 ± 2.4 g. Animals were housed in
a temperature controlled room (21–22 °C) with 12:12 h light–darkcycle, and received standard chowpellets andwater ad libitum. Animals
were randomly divided into 6 different groups for each genotype,
and were subsequently subjected to no experimental procedures
(‘baseline’/RL-−14), 14 days of hindlimb suspension (‘HS’/RL-0) or HS
followed by 1, 2, 3, or 5 days of reloading (RL-1, -2, -3, -5, respectively).
The group size was n = 8 except for MGSK-3β KO RL-5 (n = 7) and
baseline for both genotypes (n = 9). A modiﬁed version of the HS/RL
model [82] has previously been described [83]. In brief, a tail harness
was placed while mice were lightly anesthetized using isoﬂurane inha-
lation. HSwas accomplished using a tail suspension device consisting of
a plastic-coated iron wire taped around the mouse's tail and connected
to a swivel hook to allow circular motility. The latter was attached to a
Teﬂon-coated PVC ring, which slid over an iron rod spanning the length
of the cage to allow longitudinal motility. The mice were raised so as to
prevent the hindlimbs from touching the cage ﬂoor or sides. In thisway,
four HS mice could be housed in one standard cage. After two weeks of
HS, micewere again lightly anesthetized and released from the tail har-
ness and allowed to resume normal cage activity. During the whole
treatment period bodyweight andwater consumptionweremonitored,
in addition during the reloading phase chow consumption was
assessed. After euthanasia with sodium pentobarbital at the indicated
time points, lower leg muscles were excised using standardized dissec-
tion methods, cleaned of excess fat and tendon/connective tissue, pair
weighed on an analytical balance, snap frozen in liquid nitrogen, and
stored at−80 °C for RNA and protein extraction or part of the muscle
was embedded in Tissue-Tek O.C.T. (Sakura, Finetek, Zoeterwoude, the
Netherlands) for histological analyses. All subsequent analyses were
performed in either soleus or gastrocnemius muscle, which despite
their slightly differing anatomical positions and locomotive function,
both respond to HS and RL alterations in muscle mass.
2.2. Western blot analysis
M. gastrocnemius was grounded into powder and homogenized in
400 μl of IP lysis buffer (50 mM Tris, 150 mM NaCl, 10% glycerol, 0.5%
Nonidet P40, 1 mM EDTA, 1 mM Na3VO4, 5 mM NaF, 10 mM β-
glycerophosphate, 1 mM Na4O7P2, 1 mM dithiothreitol, 10 μg/ml
leupeptin, 1% aprotenin, 1 mM PMSF, pH 7.4) with a Polytron PT 1600
E (Kinematica). After homogenization, the samples were incubated for
15 min on a rotating wheel at 4 °C and spun for 30 min at maximum
speed (20,817 ×g) in a centrifuge cooled to 4 °C. The supernatant was
aliquoted, snap-frozen, and stored without sample buffer at −80 °C
until analysis. A portion of the supernatant was saved for protein deter-
mination, prior to the addition with 4× Laemmli sample buffer (0.25 M
Tris–HCl pH 6.8; 8% (w/v) SDS; 40% (v/v) glycerol; 0.4 MDTT and 0.04%
(w/v) Bromophenol Blue). The samples were boiled for 5 min at 95 °C
and stored at −80 °C. Total protein was assessed by the Thermo
Scientiﬁc Pierce BCA Protein Assay kit (Pierce Biotechnology, IL, USA)
according to themanufacturer's instructions. The pellet fractionwas re-
suspended in IP lysis buffer and homogenizedwith a Polytron PT 1600 E
(Kinematica), subsequently 4× Laemmli sample buffer was added
and boiled for 5 min at 95 °C and stored at −80 °C. For SDS-PAGE
0.2 μg–15 μg of protein was loaded per lane and separated on a
Criterion™XTPrecast 4–12% Bis-Tris gel (Bio-Rad, #3450124), followed
by transfer to a 0.45 μmWhatman® Protran® Nitrocellulose Transfer
membrane (Whatman GmbH, #7324007) by electroblotting (Bio-Rad
Criterion Blotter) (Bio-Rad, Hercules, CA, USA). For the pellet fraction
containing protein loaded samples the membrane was stained with
Ponceau S solution (0.2% Ponceau S in 1% acetic acid; Sigma-Aldrich
Chemie) to quantify total protein loading. The membrane was blocked
for 1–2 h at room temperature in 5% (w/v) NFDM (non-fat dried
milk) (ELK, Campina, the Netherlands) diluted in TBS-Tween-20
(0.05%). Nitrocellulose blots were washed in TBS-Tween-20 (0.05%)
on a rotating platform, followed by overnight (o/n) incubation at 4 °C
with speciﬁc antibodies directed against: p-mTOR (Ser2448) (#2971),
mTOR (#2983), p-Akt (Ser473) (#9271), Akt (#9272), p-GSK-3β
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(#2708), 4E-BP1 (#9452), p-FoXO1 (Ser256) (#9461), FoXO1 (#2880),
p-FoXO1/3a (Thr24) (#9946), and GAPDH (#2118) (all from Cell Sig-
naling Technology, Inc., Danvers, MA), myosin heavy chain fast
(MyHC-f/MHC-2) (#M4276, Sigma-Aldrich) all diluted in TBS/0.05%
Tween-20 with or without 5% BSA/NFDM. After 3 washing steps of
10 min each, the blots were probed with a peroxidase conjugated
secondary antibody (Vector Laboratories, #PI-1000), and visualized by
chemiluminescence using Supersignal® WestPico Chemiluminescent
Substrate (Pierce Biotechnology, Inc.) according to the manufacturers'
instructions and exposed to ﬁlm (Biomax light ﬁlm, KODAK) or live im-
aged (Bio-Rad chemidoc XRS). Western blot images were quantiﬁed
using the Quantity One analysis software from Bio-Rad. For analyses,
gels were loadedwith bothWT andMGSK-3β KO samples, and samples
of the same groupwere distributed overmultiple gels to allow compar-
isons to RL-0 (HS).
2.3. RNA isolation and assessment of mRNA abundance by RT-qPCR
M. gastrocnemius was grounded into powder and approximately
10 mg of sample was suspended and lysed in RLT solution containing
1% β-mercaptoethanol. Samples were further processed according to
manufacturer's instructions of the RNeasy ﬁbrous tissue Mini Kit
(Qiagen, Venlo, the Netherlands) including the on-columnDNase treat-
ment. RNA was reconstituted in 50 μl RNase free water and stored at
−80 °C. The RNA concentrationsweremeasured spectrophotometrical-
ly using a Nanodrop® ND-1000 UV–Vis spectrophotometer. RNA was
diluted N5× in ddH2O and 400 ng of RNA was reverse transcribed to
cDNA using the Transcriptor ﬁrst strand cDNA synthesis kit (Roche
Diagnostics GmbH, Mannheim, Germany) with anchored oligo-dT
primers according to the manufacturer's conditions for generating
cDNA fragment of 4 kb in a ﬁnal reaction volume of 20 μl. This cDNA
was used for the quantiﬁcation of transcript levels by reverse transcrip-
tion quantitative PCR (qPCR) analysis. qPCR primers used, were de-
signed using Primer Express 2.0 software (Applied Biosystems, Foster
City, CA), and obtained from Sigma Genosys (Haverhill, UK). qPCR
reactions (16 μl ﬁnal volume) contained SensiMix SYBR Hi-ROX Kit
(Quantace-Bioline, London, UK) with 300 nM primers and were run in
a 384-well MicroAmp Optical 384-Well Reaction Plate (Applied
Biosystems, Nieuwerkerk a/d IJssel, the Netherlands) on a 7900HT Fast
Real-Time PCR System (Applied Biosystems). Relative cDNA starting
quantities for the samples were derived by the standard curve method.
Standard curve samples were generated by serial dilution of pooled
cDNA samples. Starting quantities were obtained by extrapolating Ct
values on the standard curve. The expression of the genes of interest
was normalized with a correction factor derived by GeNorm [84]. This
factor was determined for each group individually to reduce variation
in data resulting from biological spread and analytical imperfections,
as reference gene expression between time points responded signiﬁ-
cantly, in line with observations by others [85]. The GeNorm
correction factor was based on the expression levels of GAPDH,
RPL13A, ARBP, Calnexin and β2M as reference genes.
2.4. Immunohistochemical analyses
Histological analysis of cell proliferation andmyoﬁber cross section-
al area was performed on M. soleus, as ﬁber type composition and CSA
are less heterogeneous compared to M. gastrocnemius [86]. Further-
more compared to the gastrocnemius, the soleus muscle has greater
load-sensitivity and thus greater morphological remodeling processes
are expected to be undertaken during the reloading phase [87]. OCT-
embedded, frozen M. soleus sections were cut (5 μm), air dried, treated
with 0.5% Triton X-100 in PBS, incubated with primary anti-myosin
heavy chain (MyHC)-I [Developmental Studies Hybridoma Bank
(DSHB), University of Iowa, Ames, IA], anti-MyHC-IIa (DSHB), and
anti-laminin (Sigma, Zwijndrecht, the Netherlands) followed bysecondary antibodies labeled with Alexa Fluor 555, Alexa Fluor 488,
and Alexa Fluor 350 (Invitrogen, Breda, the Netherlands). Unstained ﬁ-
bers were considered type IIX/B ﬁbers. After staining, all images were
digitally captured using ﬂuorescence microscopy (Nikon Instruments
Europe). Image processing and quantitative analyses were done using
the Lucia 4.81 software package. The mean ﬁber CSA of each muscle
was calculated by analyzing on average N200 ﬁbers per muscle. Ad-
ditionally frozen M. soleus sections were cut (5 μm), were air dried,
treated with 0.5% Triton X-100 in PBS, and incubated with primary
anti-laminin (Sigma, Zwijndrecht, the Netherlands) and Ki-67
(Biocare medical/klinipath,Pigeons, the Netherlands) followed by
secondary antibodies labeled with Alexa Fluor 488, and Alexa Fluor
350 (Invitrogen, Breda, the Netherlands) and propidium iodide (PI)
for nuclear staining. After staining, all images were digitally captured
using ﬂuorescence microscopy (Nikon Instruments Europe). Image
processing and quantitative analyses were done using the Lucia 4.81
software package. Double stained (PI and Ki-67) nuclei were counted
as proliferating nuclei and divided by the number of ﬁbers per muscle
section analyzed to determine the proliferation level for that speciﬁc
muscle.
2.5. Statistical analysis
Statistical data analysis was performed (n= 4–9) to allow compar-
isons betweenWild-type littermate Ctrl (WT) vs. MGSK-3β KOmice at
speciﬁc timepoints, andwithin genotypes between a speciﬁc time point
vs. RL-0 (HS). Signiﬁcant differences were detected with a non-
parametric Mann–Whitney U test, p b 0.05 or smaller as indicated in
each ﬁgure. Data are expressed as mean ± SEM. Data were analyzed
using SPSS/PC+ (Statistical Package for the Social Sciences, Version
22.0 for Windows; SPSS; Chicago, IL).
3. Results
3.1. Muscle speciﬁc deletion of GSK-3β accelerates bodyweight recovery
and muscle MGF expression during muscle reloading
GSK-3β protein content was reduced (~95%) inM. gastrocnemius of
MGSK-3β KO compared to WTmice (Fig. 1A), whereas GSK-3α protein
levels were unaffected. This allowed us to address GSK3β functions that
are either non-redundant with GSK-3α, or are dependent on total GSK3
levels. eIF2Bε (Ser539) phosphorylation, a downstream target of GSK-3
enzymatic activity [88], was signiﬁcantly lower in MGSK-3β KOmuscle
(p b 0.05) (Fig. 2D). Hindlimb suspension (HS) resulted in approximately
10% bodyweight (BW) loss (Fig. 1B, left panel). The genotypic difference
(p b 0.05) in the initial BW loss after two days of HS (Fig. 1B, left panel)
suggested a short term (initial 24–72 h of HS) protective effect in
MGSK-3β KO mice compared to Wild-type Ctrl (WT) mice. During the
ﬁve day reloading (RL) period BW signiﬁcantly increased (p b 0.001)
compared to HS (RL-0) for both genotypes (Fig. 1B, right panel). Howev-
er, compared to WT, BW recovery following ﬁve days of RL was signiﬁ-
cantly greater in MGSK-3β KO mice (6.7 ± 1.2% v.s. 11.3 ± 0.8%,
p b 0.05). Fourteen days of HS comparably decreased muscle mass in
both WT and MGSK-3β KO mice (16.9 ± 2.7%, p b 0.001 and 16.3 ±
2.2%, p b 0.001, respectively, Fig. 1C, left panel). Importantly, alterations
in unloading-sensitive muscle mass were attributable to unloading, as
no changes in the unloading-insensitive M. extensor digitorum longus
(EDL) were observed (data not shown). Subsequent hindlimb RL
showed a comparable but not statistical signiﬁcant increase in gastroc-
nemius muscle mass for WT and MGSK-3β KO (6.6 ± 2.6% and 5.8 ±
4.6%, Fig. 1C, right panel). Accordingly, the evaluation of myoﬁbrillar
protein accretion revealed increases inMHC-2 (glycolytic isoform) con-
tent in M. gastrocnemius homogenates following 5 days RL (38.7 ±
7.6%, p b 0.01 and 27.8 ± 5.6%, p b 0.01, Fig. 1D, right panel), in line
with netmuscle tissue accretion. Expression ofMechano Growth Factor
(MGF), produced during muscle remodeling [89], was clearly induced
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Fig. 1.Muscle speciﬁc deletion of GSK-3β accelerates bodyweight recovery and muscle MGF expression during muscle reloading. (A) M. gastrocnemius protein lysates were subjected to
Western blot and GSK-3β knockdown levels and GSK-3α expression levels were assessed (WT/MGSK-3β KO n = 2). Muscle-speciﬁc GSK-3β KO or littermate controls (WT) were sub-
jected to 14 days of hindlimb suspension (HS). (B) Bodyweight (BW) was monitored and expressed as percentage change of starting bodyweight during HS (left panel, WT n = 40,
MGSK-3β KO n=39). Following the completion of HS and during reloading (RL) BW, expressed as percentage change of BWat the start of RL (RL-0/HS; right panel, bothWT/KO decrease
with n = 8 increments). (C) Paired gastrocnemius muscle weights were determined at baseline (‘RL-−14’) and after HS (‘RL-0’; left panel). Alternatively, during RL M. gastrocnemius
weights were expressed as percentage of HS (RL-0) muscle weight (right panel). (D) Glycolyticmyosin heavy chain (MHC-2) protein contents were detected in re-solubilizedmuscle ho-
mogenate pellet fraction, normalized to total protein determined by Ponceau-S staining, and expressed as fold change of HS (RL-0). (E) Mechano Growth Factor (MGF)mRNA levelswere
determined during baseline and following HS (left panel), or during RL (right panel). MGF expression levels during RL are presented as fold change compared to RL-0 (HS) to illustrate
reloading-induced changes. (C–E group size was n = 8 except for MGSK-3β KO RL-5 n = 7 and baseline for both genotypes n = 9). Averages ± SEM are presented, *: Wild-type Ctrl
vs.MGSK-3βKOat that speciﬁc time point, †: indicates time effect compared to RL-0 (HS) forWild-type Ctrl and #: indicates time effect compared to RL-0 (HS) forMGSK-3βKO; 1 symbol
equals p b 0.05, 2 symbols equal p b 0.01, and 3 symbols equal p b 0.001.
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both WT and MGSK-3β KO M. gastrocnemius (Fig. 1E, right panel). Al-
though MGF expression levels were not signiﬁcantly different between
genotypes at baseline (RL-−14) or after HS (RL-0) in Fig. 1E (left panel),HS increased MGF expression compared to baseline levels in MGSK-3β
KO but not WT (50.9 ± 4.1%, p b 0.01 vs. 9.39 ± 7.6% n.s.). During RL,
MGF expression was up-regulated (~two-fold, p b 0.01) in both WT
and MGSK-3β KO (Fig. 1E, right panel). However, MGF expression
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gastrocnemius was prepared for gene expression analysis and (A) REDD1 (B) KLF-15 and (C) FoXO1 were detected to determine protein degradation signaling status after HS and fold
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compared to WT (3.0 ± 0.3-fold, p b 0.001 vs. 2.2 ± 0.2-fold, p b
0.001, Fig. 1E, right graph). Combined, these data indicate that
reloading-induced muscle remodeling may be affected by GSK-3β.
3.2. Activation of Akt–mTOR signaling duringmuscle reloading is not affect-
ed by the absence of GSK-3β
Hindlimb reloading initiates the muscle remodeling process which
involves adjusting the protein turnover balance regulated by protein
synthesis and degradation signaling [78,90–92]. Akt (Ser473) phos-
phorylation is lower in MGSK-3β KO compared to WT at baseline
(RL-−14) (p b 0.05, Fig. 2B). Akt-phosphorylation levels were not af-
fected by HS (RL-0) in WT but were increased in MGSK-3β KO (3.6 ±
15.7% vs. 49.8±13.6%, p b 0.05, Fig. 2B), and thereby no longer genotyp-
ically different fromWT. At RL-1 Akt-phosphorylation increased, com-
pared to HS (RL-0), for WT and MSGK-3β KO (77.8 ± 8.8%, p b 0.01
and 97.0 ± 15.1%, p b 0.05, respectively, Fig. 2B). During further RL
days, Akt phosphorylation decreased again to HS comparable levels for
both genotypes. After HS downstream from Akt, inactivating GSK-3β
(Ser9) phosphorylation was increased by ~50% inWT (Fig. 2C). Follow-
ingHS, GSK-3β phosphorylation did not signiﬁcantly increase until RL-5
(39.2 ± 8.9%, p b 0.05, Fig. 3C). This coincided with a similar increase in
WT Akt phosphorylation (30.5 ± 18.1%, Fig. 2B) at RL-5. As expected,
eIF2Bε (Ser539) phosphorylation, downstream target of GSK-3β phos-
phorylation [88], was signiﬁcantly lower in MGSK-3β KO (p b 0.05)
and did not alter throughout HS–RL (Fig. 2D). Although in WT muscle
eIF2Bε phosphorylation did not signiﬁcantly change during HS-RL,
phospho levels appeared to inversely reﬂect GSK-3β phosphorylation
changes at RL-0 and RL-5 (Fig. 2D and C).
mTOR (Ser2448) phosphorylation levels were unaltered after HS
and not different between genotypes (Fig. 2E). However, mTOR phos-
phorylation increased as of RL-1 in both WT and MGSK-3β KO muscles
(2.7 ± 0.3-fold, p b 0.01, and 3.1 ± 0.5-fold, p b 0.001, no genotypic
difference), leveling off above HS levels at RL-2 and later time points
(N1.5-fold, p b 0.05), with no genotypic effect of GSK-3β ablation
(Fig. 2E). S6K (Thr389) phosphorylation, a major downstream target
of mTOR and effector of mRNA translation capacity, was not detectable
at either baseline (RL-−14) or after HS (RL-0) for either genotype
(Fig. 2F). However, the initiation of RL clearly increased S6K phosphor-
ylation (Fig. 2F). Following the initial increase on RL-1, S6K phosphory-
lation decreased on RL-2 and RL-3, while it increased again at RL-5 for
bothWT andMGSK-3βKO (1.3±0.3 AU and 2.9±0.7 AU, respectively,
Fig. 2F) with no statistically signiﬁcant genotypic effects throughout RL.
This biphasic response was not observed in mTOR phosphorylation
changes (Fig. 2C), but was apparent in Akt phosphorylation changes
(Fig. 2B). Phosphorylation levels of the suppressor of mRNA translation
initiation 4E-BP1 were, in line with S6K and mTOR, unchanged after HS
(Fig. 2G). However, RL initiation increased 4E-BP1 phosphorylation
evidenced by a shift from the relative proportion of un-phosphorylated
to hyper-phosphorylated (inactivating) 4E-BP1. Hyper-phosphorylation
of 4E-BP1 increased for both WT and MSGK-3β KO (42.2 ± 0.7%,
p b 0.01 and 76.8 ± 10.9%, p b 0.01, respectively) on RL-1 and remained
elevated subsequently till RL-5 for both genotypes (N30%, p b 0.01,
Fig. 2G). The inverse was observed for un-phosphorylated 4E-BP1; with
no observed effect of GSK-3β ablation on 4E-BP1 phosphorylation distri-
bution during HS–RL (Fig. 2G). Thus, apart from its direct target eIF2Bε,
the deletion of GSK-3β does not appear to affect increased protein
synthesis signaling in atrophied muscle in response to RL.
3.3. Differential effects of GSK-3β deletion on changes in the expression of
glucocorticoid sensitive regulators of protein turnover signaling during
muscle unloading and reloading
Skeletal muscle protein turnover is affected by glucocorticoid (GC)
receptor (GR) signaling [39,93–96]. GR-mediated transcription ofREDD1 has been implicated in the inhibition of protein synthesis [20,
97]. HS was accompanied by an up-regulation of REDD1 expression in
WT and MGSK-3β KO (3.6 ± 0.6-fold, p b 0.001 and 2.1 ± 0.3-fold,
p b 0.05, respectively), which was most pronounced in WT muscle
(1.7-fold higher than in MGSK-3β KO, p b 0.05; Fig. 3A, left panel). The
subsequent decrease in REDD1 expression after RL-1 observed in WT
(1.8-fold, p b 0.01) was absent in MGSK-3β KO (Fig. 3A, right panel).
From RL-2 onwards, both WT (p b 0.001) and MGSK-3β KO (p b 0.01)
displayed N70% decrease in REDD1 mRNA expression compared to
RL-0 (Fig. 3A, right panel).
KLF-15 [98,99], and FoXO1 [98,100] are two transcriptional regula-
tors of proteolysis affected by the GR. KLF-15 was not altered after HS
in WT, but increased in MGSK-3β KO (1.0 ± 0.1-fold vs. 1.7 ± 0.2-
fold, p b 0.001, respectively; Fig. 3B, left panel), with levels differing be-
tweenWT andMGSK-3β KO (1.7-fold, p b 0.001; Fig. 3B, left panel). Ini-
tiation of RL decreased KLF15 expression until RL-5 for both WT and
MGSK-3β KO (46.7 ± 5.8%, p b 0.001 and 66.3 ± 8.3%, p b 0.01, respec-
tively), but this decrease started already at RL-2 inMGSK-3β KOmuscle
(1.6 ± 0.1-fold, p b 0.01) and was more pronounced compared to WT
(RL-2 and RL-3, p b 0.01; Fig. 3B, right panel). Interestingly FoXO1 ex-
pression changes throughoutHS–RLwere relatively similar to KLF15 ex-
pression changes (Fig. 3C and B, respectively). FoXO1 total protein
content was increased after HS for both WT and MGSK-3β KO (1.2 ±
0.1-fold and 1.4 ± 0.1, p b 0.05, respectively; Fig. 3D–E) and remained
relatively unchanged until RL-5, when it decreased to RL- –14 (BL)
comparable levels (1.2 ± 0.1-fold and 1.5 ± 0.1, p b 0.05, respectively;
Fig. 3E). FoXO activity is strongly regulated by its phosphorylation
status, which facilitates its nuclear exclusion [101]. HS resulted in in-
creased phosphorylation of FoXO1, which was more pronounced in
WT (Thr24 and Ser256, 2.1 ± 0.2-fold and 1.9 ± 0.3-fold, respectively,
p b 0.05) compared to MGSK-3β KO (Thr24 and Ser256, 1.8 ± 0.1-
fold, p b 0.01 and 1.5 ± 0.2-fold, respectively; Fig. 3F and G). During
RL FoXO1 Thr24 phosphorylation appeared to decrease for both geno-
types, but only signiﬁcantly in MGSK-3β KO (N25% RL-2 and RL-3, p b
0.05; Fig. 3F). In contrast, at RL-5 FoXO1 phosphorylation strongly in-
creased compared to RL-0 for both WT (Thr24 and Ser256, 2.1 ± 0.2-
fold, p b 0.001 and 1.4 ± 0.1-fold, respectively) and MGSK-3β KO
(Thr24 and Ser256, 2.9 ± 0.3-fold, p b 0.01 and 1.8 ± 0.1-fold, p b 0.05,
respectively; Fig. 3F–G). Considering the extensive regulation of FoXO
during HS and RL in both genotypes, FoXO transcriptional targets in-
volved in muscle protein degradation were subsequently investigated.
3.4. Expression of proteolysis mediators is decreased during muscle
reloading and differentially affected by the absence of GSK-3β
Atrogin-1 gene expression was lower at baseline (RL-−14) in
MGSK-3β KO than WT (~1.5-fold, p b 0.01), and increased similarly
following HS in both WT and MGSK-3β KO (1.5 ± 0.2-fold, p b 0.05
and 1.6 ± 0.2-fold, respectively), sustaining the genotypic difference
(p b 0.05; Fig. 4A, left panel). With RL, atrogin-1 gene expression levels
decreased similarly for WT and MGSK-3β KO till RL-5 (N3.5-fold,
p b 0.01; Fig. 4A, right panel). Contrary to atrogin-1, MuRF1 gene ex-
pression was not different between genotypes at baseline, nor signiﬁ-
cantly induced after HS in either WT or MGSK-3β KO (Fig. 4B, left
graph). RL-associated MuRF1 gene expression suppression (N2.5-fold,
p b 0.05; Fig. 4B, right panel) occurred more rapidly in MGSK 3β KO,
similar to REDD1 and FoXO1 (Fig. 3A and C, right panels). Interestingly,
MuRF1 expression transiently increased in both WT and MGSK-3β KO
muscles at RL-3 (1.4 ± 0.1-fold and 1.8 ± 0.2-fold compared to RL-2,
respectively; Fig. 4B, right panel), corresponding with the biphasic re-
sponse of FoXO1 phosphorylation (Fig. 3F–G). Autophagy mediator
BNIP3 baseline mRNA levels were unaffected by muscle-speciﬁc GSK-
3β ablation (Fig. 4C, left panel). Although HS increased BNIP3 expres-
sion in both WT and MGSK-3β KO (13.6 ± 5.7%, p b 0.05 and 64.8 ±
8.8%, p b 0.001, respectively), it resulted in a signiﬁcantly different ge-
notypic response (p b 0.001; Fig. 4C, left panel). BNIP3 expression
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Fig. 4. Expression of proteolysis mediators is decreased duringmuscle reloading and differentially affected by the absence of GSK-3β. M. gastrocnemius was prepared for gene expression
analysis and (A) atrogin-1, (B) MuRF1 and (C) BNIP3 were detected to determine possible effects of protein degradation signaling status after FoXO1 phosphorylation changes due to HS
and fold change compared to start reloading (RL-0) gene expression levels duringRL. (A–C group sizewas n=7–9 for bothWT andMGSK-3βKO). Averages± SEMare presented, *:Wild-
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1: 1.4 ± 0.1-fold, p b 0.01 and 1.2 ± 0.1-fold, respectively), but subse-
quently decreased until RL-5 for both genotypes (N1.9-fold, p b 0.001).
However, BNIP3 expression decreased more rapidly in MGSK-3β KO
compared toWT on RL-2 and RL-3 (p b 0.05 and p b 0.001, respectively;
Fig. 4C, right panel).
3.5. Rapid induction of cell proliferation uponmuscle reloading is not affect-
ed by GSK-3β ablation
To assesswhether HS–RL inducedmuscle remodeling involves satel-
lite cell proliferative responses which are affected by muscle-speciﬁc
GSK-3β ablation, Cyclin D1 and PCNA gene expression levels were
determined in the gastrocnemius muscle. Although at baseline
(RL-−14) Cyclin D1 expression was ~1.5-fold (p b 0.05) lower in
MGSK-3β KO compared to WT, HS decreased Cyclin D1 expression
for both WT and MGSK-3β KO to comparable levels (2.2 ± 0.2-fold;
p b 0.001 and 1.4 ± 0.1-fold, respectively; Fig. 5A, left panel). Cyclin
D1 levels rapidly increased with RL in both WT and MGSK-3β KO
(RL-1: 4.3 ± 0.7-fold, p b 0.001 and 5.0 ± 0.2-fold, p b 0.001, respec-
tively; Fig. 5A, right panel), and remained elevated throughout RL for
both genotypes (~2.5-fold, p b 0.01; Fig. 5A, right panel). PCNA base-
line expression was not signiﬁcantly altered by HS or genotypically
different (Fig. 5B, left panel). Similar to Cyclin D1, PCNA gene expression
rapidly increased with RL in both WT and MGSK-3β KO (RL-1: 3.5 ±
0.5-fold, p b 0.05 and 3.1 ± 0.6-fold, p b 0.05, respectively; Fig. 5B,
right panel), and displayed a biphasic response. In contrast to Cyclin
D1, both WT and MGSK-3β KO PCNA expression levels had returnedto RL-0 (HS) comparable levels at RL-5 (Fig. 5B, right panel). A Ki-67
protein staining was used to visualize cell proliferation in the soleus
muscle using immunohistochemistry (Fig. 5C). Very few positive nuclei
were observed at baseline (RL-−14), or directly following HS (RL-0). In
contrast, striking increases in cellular Ki-67 staining appeared on RL-
3 and RL-5 (N18-fold; Fig. 5D), indicating active cell proliferation in
the soleus muscle. However, GSK-3β ablation did not signiﬁcantly af-
fect the number of proliferating cells.
3.6. Absence of GSK-3β enhances myogenesis-associated gene expression
upon muscle reloading
To assesswhether the increase in cell proliferationwas accompanied
by a myogenic regenerative response, satellite cell activation and
myogenesis were probed. PAX-7 expression was not changed after HS
for both WT and MGSK-3β KO (Fig. 6A, left panel). Similar to Cyclin
D1 and PCNA, PAX-7 transcript levels strongly increased on RL-1
in both WT and MGSK-3β KO (1.6 ± 0.3-fold and 1.9 ± 0.3-fold,
p b 0.01, respectively), and decreased at RL-5 (1.5 ± 0.1-fold and
1.9 ± 0.1-fold, p b 0.01, respectively; Fig. 6A, right panel) to levels
below RL-0 (HS). However, only in WT, PAX7 expression levels
progressed with a biphasic response throughout RL (WT vs. MGSK-3β
KO ~2.5-fold, p b 0.01 on RL-3; Fig. 6A right panel), similar to patterns
of Cyclin D1 and PCNA expression.M-cadherin transcript levelswere el-
evated in response to HS only in MGSK-3β KO, resulting in a difference
betweenWT andGSK3-KO followingHS (RL-0: 1.2±0.1-fold and 1.7±
0.1-fold, p b 0.001, respectively; Fig. 6B, left panel). RL induced M-
cadherin expression changes progressed very similar to PAX7 (Fig. 6A
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Fig. 5. Rapid induction of cell proliferation upon muscle reloading is not affected by GSK-3β ablation. M. gastrocnemius was prepared for gene expression analysis and (A) Cyclin D1 and
(B) PCNA were detected to determine cell proliferation status due to HS and fold change compared to start reloading (RL-0) gene expression levels during RL (A–B group size was n = 7–9
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of positive nuclei over total number of ﬁbers thereby identifying proliferating nuclei per section. (C group size was n = 2–4 for both WT and MGSK-3β KO). Averages ± SEM
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observed only for WT.
Muscle Regulatory Factor (MRF)Myf5 increased after HS for bothWT
and MGSK-3β KO (RL-0: 1.4 ± 0.1-fold, p b 0.05 and 1.8 ± 0.2-fold,
p b 0.01, respectively; Fig. 6C, left panel), and did not signiﬁcantly
change during the subsequent RL phase. In contrast to the other two
myogenic differentiation associated markers, baseline MyoD expression
was lower in MGSK-3β KO compared to WT (RL-−14: 1.6-fold,
p b 0.001; Fig. 6D, left panel). After HS MyoD expression only signiﬁ-
cantly increased in MGSK-3β KO (RL-0: 1.8 ± 0.2-fold, p b 0.001;
Fig. 6D, left panel), abolishing the genotypic difference. MyoD expression
transiently increased in WT and MGSK-3β KO on RL-1 (2.3 ± 0.5-fold,p b 0.01 and 2.9 ± 0.2-fold, p b 0.001, respectively), which was slightly
more pronounced in MGSK-3β KO compared to WT muscle (1.3-fold,
p b 0.05; Fig. 6D, right panel). Myogenin expression appeared slightly
increased in WT and MGSK-3β KO muscles following HS (RL-0: 1.5 ±
0.2-fold, p b 0.05 and 1.6 ± 0.3-fold, p = 0.052, respectively; Fig. 6E,
left panel). RL induced increases in myogenin expression followed a
biphasic pattern in both WT and MGSK-3β KO, with marked induction
on RL-1 (2.6±0.3-fold, p b 0.01 and 5.5±0.6-fold, p b 0.001, respective-
ly; Fig. 6E, right panel),whichwas alsomore pronounced inMGSK-3βKO
(2.1-fold, p b 0.01; Fig. 6E, right panel). Altogether these data revealed
subtle increases in the early myogenic differentiation response during
RL in regenerating muscle of MGSK-3β KO compared to WT mice.
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soleus
Considering these consistent subtle effects of GSK-3β ablation on
muscle unloading–reloading induced remodeling in M. gastrocnemius,
GSK-3β-dependency of loading-induced remodeling was ﬁnally evalu-
ated in the small, but very load-sensitive M. soleus. In line with ﬁber-speciﬁc recombination of the ﬂoxed GSK-3β alleles, GSK-3β protein
content was ~40% decreased in M. soleus MGSK-3β KO compared to
WT mice (Fig. 7A). After HS, soleus muscle weight decreased compa-
rably in WT and MGSK-3β KO (52.1 ± 3.5%, p b 0.001 and 58.5 ±
3.2%, p b 0.001, respectively; Fig. 7B), in line with the observations
in M. gastrocnemius weight loss (Fig. 1C). Correspondingly, compared
to baseline, soleus muscle ﬁber cross sectional area (CSA) decreased
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Fig. 7. GSK-3β deﬁciency does not prevent disuse-induced atrophy in M. soleus. (A) M. soleus protein lysates were subjected toWestern blot and GSK-3β knockdown levels and GSK-3α
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51.6 ± 3.1%, p b 0.001; Fig. 7C). The CSA reduction following HS was
more evident in M. soleus of MGSK-3β KO compared to WT (RL-0:−14%, p b 0.05; Fig. 7C–D) following HS, which was further reﬂected
in a slightly more leftward shift in ﬁber size distribution for MGSK-3β
KO compared to WT (Fig. 7E).
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RL-0 (HS) for Wild-type Ctrl and #: indicates time effect compared to RL-0 (HS) for MGSK-3β KO; 1 symbol equals p b 0.05, 2 symbols equal p b 0.01, and 3 symbols equal p b 0.001.
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area in GSK-3β deﬁcient soleus muscle
Soleus muscle mass increased during RL for both MGSK-3β KO and
WT.However, this increase occurredmore rapidly inMGSK-3βKO com-
pared to WT mice (RL-1 vs. RL-0: 20.6 ± 3.8%, p b 0.05, and 2.8 ± 5.2%
n.s., respectively; KO vs. WT: p b 0.05), and was more pronounced in
MGSK-3β KO muscle (RL-5: 43.7 ± 6.4%, p b 0.001, and 28.9 ± 5.2%,
p b 0.01, respectively; MGSK-3β KO vs. WT: p b 0.05, Fig. 8A). Remark-
ably, even after 5 days of RL, soleus muscle mass recovery was not
accompanied by a comparable increase in muscle ﬁber CSA for eithergenotype (Fig. 8B). Nevertheless, during RL there was a trend towards
increased ﬁber CSA compared to HS, but only in MGSK-3β KO vs. WT
after 5 days of RL (15.8 ± 3.6%, p = 0.086 vs.−5.9 ± 6.8%, p = 0.291,
respectively; Fig. 8B). GSK-3β levels in M. soleus were only reduced
by ~40% (Fig. 7A). As this may reﬂect ﬁber type-speciﬁc recombination
as a consequence of the MLC-1f promoter driven Cre-recombinase ex-
pression, CSA change during HS–RL was determined in analyses of indi-
vidual ﬁber types according to slow or fast twitch myosin heavy chain
(MHC) composition. Based on MHC-1 or -2A-immunoreactivity, these
were divided intoMHC-1,MHC-2A, hybridMHC-1/MHC-2A or negative
(MHC-2B and/or MHC-2X) ﬁbers. Fiber type distribution was largely
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out of MHC-1 and -2A ﬁbers (Fig. 8C). MHC-1 ﬁber CSA did not change
during RL in WT muscle, whereas a trend to increase was observed in
MGSK-3β KO (RL-5: 0.1 ± 8.5%, p = 0.808 vs. 14.3 ± 5.9%, p = 0.086,
respectively; Fig. 8D, left panel). Importantly, only inMGSK-3βKOmus-
cle, MHC-2A ﬁber CSA signiﬁcantly increased during RL (RL-5: 2.7 ±
7.6% vs. 20.6 ± 2.7%, p b 0.05, respectively; Fig. 8D, right panel), and
MHC-2A ﬁber CSA at this time point was signiﬁcantly (p b 0.05) in-
creased in MGSK-3β KO compared to WT muscle. This difference in
the recovery of MHC-2A ﬁber CSA during RL is further illustrated
by the clear rightward shift in ﬁber size distribution between RL days
0–3–5 in MGSK-3β KO, but not for WT soleus muscle (Fig. 8E). These
data underscore the subtle, but consistent effects of GSK-3β deﬁciency,
indicative of accelerated muscle regeneration during recovery from
disuse-induced muscle atrophy.
4. Discussion
In this study muscle speciﬁc deletion of GSK-3β (MGSK-3β KO) was
used to uncover functions in muscle mass modulation that are either
non-redundant with GSK-3α, or depend on total GSK-3 levels. The
main hypothesis that muscle mass recovery of atrophied muscle is
accelerated in the absence of GSK-3β was tested in a reversible
disuse-induced muscle atrophy model. Reloading-associated changes
in muscle protein turnover were not affected by the absence of
GSK-3β. However, the extent and kinetics of satellite cell activation,
proliferation andmyogenic differentiation during reloading revealed co-
herent effects of GSK-3β absence, suggestive of accelerated myonuclear
accretion. This was accompanied by a subtle but consistent increase in
reloading-induced muscle mass accretion in GSK-3β KO muscle.
Combined, these data reveal a role for GSK-3 in muscle regeneration-
associated myogenesis and myonuclear accretion, independent of the
regulation of muscle protein turnover, during the recovery of disuse-
atrophied muscle.
Although themain hypothesis addressed in this work concerned the
role of GSK-3 in muscle regeneration following unloading-induced
muscle atrophy, previous work by others [102] demonstrated myotube
hypertrophy in response to GSK-3 inhibition. In line, muscle-speciﬁc
over-expression of IGF-I [64] correlates with GSK-3β inactivation and
muscle hypertrophy [103], suggesting that the abrogation of GSK-3β
may induce muscle mass and myoﬁber hypertrophy. Therefore, the
effect of genetic ablation of muscle GSK-3β was ﬁrst characterized
under basal conditions.
Except for the anticipated decreased phosphorylation of eIF2Bε, no
overt differences were detected in markers of protein turnover or cell
proliferation and myogenic differentiation at baseline in the absence
of GSK-3β. Nonetheless, MGF expression was slightly reduced in
MGSK-3β KO muscle. Little information is available on the regulation
of MGF transcript levels, and no previous report on effects of GSK-3
modulation on MGF expression is available. This decrease correlated
with reduced Akt phosphorylation, which may suggest attenuated
in vivo auto-paracrine signaling by this growth factor. Conversely, in a
report by Ochi et al. increasedMGFmRNA expressionwas accompanied
by elevatedAkt phosphorylation in response to exercise [104]. Although
Akt signaling is inversely related to atrogene expression [105], atrogin-1
levels were lower despite reduced Akt phosphorylation inMGSK-3β KO
mice. This is in line with in vitro studies revealing that in the absence of
GSK-3β, the induction of protein degradation signaling resulting from
Akt inhibition is markedly attenuated [75], and implicates atrogin-1
expression regulation by GSK-3β downstream of Akt.
As reduced Akt phosphorylation and atrogin-1 expression were
accompanied by decreased Cyclin D1 and MyoD levels in MGSK-3β KO
muscle, it is tempting to speculate that basal protein turnover and
myonuclear turnover are lowered in GSK-3β ablated muscle. As
atrogin-1 targets MyoD for degradation [106], lowered atrogin-1 ex-
pression may result in decreased turnover rates of MyoD protein,requiring lower MyoD mRNA expression levels to maintain MyoD pro-
tein levels. Although skeletal muscle weights did not signiﬁcantly differ,
there was a subtle but consistent tendency towards increased muscle
mass and myoﬁber CSA in the reloading soleus muscle, which was
more pronounced in the MHC-2A than MHC-1 ﬁbers. Such an increase
in ﬁber CSA in the GSK-3β KO muscle could be the consequence of in-
creased sarcomere formation, as IGF signaling and GSK-3β inactivation
stimulate this process [107]. However, it remains to be determined
whether these changes translate into improved recovery of muscle
function: in myostatin-depleted muscle, hypertrophy was evident but
this was not accompanied by increased muscle force generation [108].
Overall, these ﬁndings are in line with a previous study in these mice
in which no overt phenotypical differences on muscle and whole body
mass were observed under baseline conditions [81].
Inhibition of enzymatic activity or expression of GSK-3(β) conveyed
resistance to glucocorticoid-inducedmyotube atrophy in previous stud-
ies [75,109]. In contrast, unloading-induced gastrocnemius or soleus
muscle mass loss was not prevented nor alleviated in MGSK-3β KO
mice after 14 days of HS. In fact, myoﬁber atrophy, based on CSA analy-
sis appeared even slightly greater in GSK-3β deﬁcient muscle. Discrep-
ancies between muscle weight- and ﬁber CSA loss have also been
observed by others [110], and although these have not convincingly
been addressed, differences in interstitial ﬂuid accumulation may con-
tribute to this phenomenon [111,112]. That GSK-3β absence did not
prevent disuse-induced muscle (ﬁber) atrophy was contrary to our ex-
pectations. Redundancy between GSK-3α and -βmay account for these
results as GSK-3α levels were unaffected in MGSK-3β KO. However,
Pierno et al. showed that muscle-speciﬁc IGF-I over-expression, despite
resulting in muscle hypertrophy, did neither protect nor alleviated
disuse-induced muscle atrophy from HS, compared to control [113], in-
dicating that the inactivation of GSK-3, subsequent to increased IGF-I
signaling, is not sufﬁcient to prevent disuse-induced muscle atrophy.
Overall, no consistent alterations in the regulation of protein or
myonuclear turnover were observed in muscles of MGSK-3β KO com-
pared toWTmice following HS; in fact only minor changes— including
modestly increased atrogin-1, BNIP3 and REDD1 levels were observed
in HS WT muscle compared to baseline conditions, likely reﬂecting a
new balance in aforementioned processes associated with stabilized
muscle mass following HS [114].
Nonetheless, at day two of HS, BW loss was signiﬁcantly less in
MGSK-3β KO compared to WT mice. During the initial phase of HS, a
strong reduction in food consumption likely contributed to decrease in
BW. This semi-starvation, in combination with subjection to HS itself,
likely increases stress hormone release, leading to increased muscle
glucocorticoid signaling [115] and subsequentmuscle atrophy [116]. In-
terestingly, as glucocorticoid-induced muscle atrophy can be abrogated
by the inhibition [109] or ablation of GSK-3β in muscles (unpublished
data), the attenuated loss of BWobserved inMGSK-3βKOmice,may re-
ﬂect the prevention of GC-induced muscle atrophy during the initial
stages of HS. However, the expression of GC-sensitive genes KLF-15
and FoXO1 [98,100] was not affected at the end of HS inWTmuscle, in-
dicating an unlikely contribution of GR signaling to disuse-induced
muscle atrophy throughout HS. In line with this, denervation-induced
muscle atrophy does not require GR-signaling [117]. Interestingly,
this suggests overlapping GSK-3β and GR-dependency for distinct
atrophy-inducing cues.
Based on previous in vitro studies by our group and others, we hy-
pothesized that GSK-3β absencewould stimulatemusclemass recovery
from atrophy. In line with our hypothesis, soleus muscle mass and ﬁber
CSA regain of MGSK-3β KOmice were enhanced compared to WT after
5 days of reloading. Conversely, the modest changes in gastrocnemius
muscle weight were similar for both genotypes. This may be the conse-
quence of the difference in sensitivity of soleus versus gastrocnemius to
unloading-induced muscle atrophy leading to a greater decrease in
muscle mass in soleus; therefore allowing the detection of a signiﬁcant
increase only in soleus muscle mass as a consequence of a more robust
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reﬂecting reloading-induced myonuclear accretion were detected in
the gastrocnemius muscle that are more pronounced in MGSK-3β KO
compared to WT.
Unexpectedly, no discernable increase in soleus ﬁber CSA was ob-
served in WT and only a slight increase for MGSK-3β KO was observed
after ﬁve days of reloading, despite clear increasing muscle weights for
both genotypes. Similar discrepancies between muscle mass and ﬁber
CSA changes have been observed in rats [118] andmice [110] subjected
to hindlimb unloading and reloading and could be contributed to inter-
stitial ﬂuid accumulation during muscle regeneration [111,112]. This
may in particular has contributed to very early changes in muscle
mass observed after reloading, as increases in myoﬁbrillar protein con-
tent were not detectable prior to 5 days of reloading. In line, separate
analysis of MHC-1 and MHC-2A muscle ﬁbers revealed a moderate but
signiﬁcant increase in MHC-2A ﬁber CSA within MGSK-3β KO soleus
muscle only after 5 days of reloading. As Cre-mediated recombination
for GSK-3β ablation is directed by the MyLC-1f promoter, which is
most prominently expressed in MHC-2 type ﬁbers, this may explain
the selective increase inMHC-2Abut notMHC-1 inMGSK-3βKOmuscle
[119]. Overall these ﬁber CSA data are in line with the observed acceler-
ated muscle mass gain during RL in the absence of GSK-3β.
MGF was up-regulated in response to RL, which is in line with its
postulated role in local muscle repair, maintenance and remodeling by
association with the activation of satellite cell and IGF signaling [62,
63]. This initial increase in MGF expression is enhanced in MGSK-3β
KO muscle. IGF-I signaling inﬂuences protein synthesis [15,20–22]. Ini-
tiation of reloading (RL-1) showed a transient increase Akt phosphory-
lation in WT muscle, in line with literature [78,120]. However, in
contrast to our previous ﬁndings in the soleus muscle [78], a signiﬁcant
increase in GSK-3β phosphorylation was only observed in the later
phase of RL (RL-5) in the gastrocnemius muscle. The latter is consistent
with the attenuated responsiveness of GSK-3β phosphorylation in the
plantaris muscle [78], and could be related to the extent of atrophy a
muscle is recovering from during RL. GSK-3β phosphorylation changes
did not correlate with Akt phosphorylation, except for RL-5, but was
inversely associated with eIF2Bε phosphorylation in WT muscle,
according to literature [88]. Despite the absence of consistent changes
in gastrocnemius GSK-3β or eIF2Bε phosphorylation during RL in WT
muscle, both were clearly decreased in MGSK-3β KO muscle, which
may have yielded a more permissive state for muscle regeneration-
associated changes in protein turnover and myonuclear accretion. In
addition, this also suggests a major contribution of GSK-3β relative to
GSK-3α in the phosphorylation of this GSK-3 substrate, which is in
line with previous estimations of the relative expression of GSK-3α
and -3β [121].
In linewith Akt, mTOR phosphorylationmarkedly increasedwith RL
initiation, which was expected [120]. Phospho-mTOR levels remained
moderately up-regulated during the course of RL, in line with the
importance of mTOR related signaling for muscle recovery from disuse
inducedmuscle atrophy previously shown by Lang et al. [122]. Similarly
following literature, increased 4E-BP1 and S6K phosphorylation
reﬂected mTOR activity and persisted throughout RL [120,122,123].
Correspondingly, REDD1 expression, a negative regulator of mTORC1
signaling [15,20,97,124,125] decreased rapidly during RL. REDD1
expression decreased more sharply in WT compared to MGSK-3β KO
muscle. This likely resulted from the elevated REDD1 mRNA levels in
WT at the end of HS, as mTOR-, 4E-BP1- and S6K phosphorylation
were not affected by GSK-3β absence. This suggests that GSK-3β pres-
ence is not a limiting factor of translation initiation or capacity during
RL-induced muscle regeneration [15,20–22]. In line with this, when
GSK-3β expression was silenced in vitro using a previously described
approach [75], basal or IGF-I stimulated puromycine incorporation as
a measure of protein synthetic rate was not affected (data not shown).
In addition, this also indicates that the regulation of S6K phosphoryla-
tion by GSK-3β, as described in vitro [126], does not apply to reloadingmuscle, or may point at redundant functions of GSK-3α. Of note, S6K
phosphorylation revealed a clear biphasic induction, which did not cor-
relate with changes in mTOR, but rather with Akt phosphorylation.
Speculatively, thismay signify the initiation of a second phase of protein
synthesis, as at RL-5 muscle weights had not recovered to baseline
levels. Altogether, these data do not support a non-redundant role of
GSK-3β or dose-limiting effects of GSK3 in the regulation of protein
synthesis signaling during reloading-induced muscle regeneration,
although it cannot be ruled out that translation initiation is facilitated
in MGSK3β KO muscle in case eIF2Bε activity becomes rate-limiting
under conditions of markedly elevated protein synthesis.
In contrast to protein synthesis, protein degradation is expected to
be decreased during RL [122,127]. FoXO is a major transcriptional regu-
lator of muscle proteolysis [38,39,128]. Nevertheless, FoXO protein
abundance only decreased after ﬁve days of reloading, which may be
attributable to decreased transcription of FoXO1, as marked decreases
in its mRNA transcript levels were observed; in particular in MGSK-3β
KO muscle. As KLF-15 closely corresponded with FoXO1 expression
levels, it is tempting to implicate KLF-15 in the transcriptional regula-
tion of FoXO1 during HS and RL. In addition, the over-expression of
KLF-15 in the tibialis muscle increases FoXO1 expression [98], but no
studies previously addressed the regulation of KLF-15 or FoXO expres-
sion by GSK-3β. Increased Thr24 or Ser256 phosphorylation levels of
FoXO1 correspondedwith the second induction of Akt phosphorylation,
suggesting the initiation of a second phase of protein synthesis with
coordinated suppression of FoXO activity. Although these data do
not support the regulation of FoXO phosphorylation by GSK-3β, it
has been implicated in the regulation of FoXO1 transcriptional activi-
ty [129]. Genes involved in protein degradation that are transcriptional-
ly regulated by FoXO [38,39,128] include effectors of UPS- and ALP-
mediated proteolysis, i.e. atrogin-1 and MuRF1 [31,32,113], and BNIP3
[37,39,40], respectively, which are known to increase under muscle
atrophying conditions [122]. As expected [122,127] both atrogin-1 and
MuRF-1 mRNA expressions decreased during RL. Conversely, BNIP3
expression transiently increased, in line with literature [127], and
subsequently decreased throughout further RL. Compared to the
UPS markers, this differential response of BNIP3 to reloading is corre-
sponding to the notion that autophagy is involved in the remodeling
and maintenance of the skeletal muscle [130]. Although the reduction
of MuRF1 and BNIP3 levels were slightly accelerated in MGSK-3β KO
muscle, overall no deﬁning role of GSK-3β absence on reloading-
induced suppression of effectors of proteolysis was apparent.
These data show for the ﬁrst time that muscle mass gain in response
to disuse-inducedmuscle atrophy reloading not only involves increases
in protein synthesis signaling, but that reloading is also accompanied by
marked down-regulation of protein degradation signaling. Overall,
these changes in protein turnover regulation were unaffected by
absence of GSK-3β.
In parallel to the balance between muscle protein synthesis and
degradation, myonuclear turnover may also contribute to muscle mass
regulation [10]. Myonuclear accretion during muscle regeneration
involves satellite cell activation, proliferation, and differentiation and
fusion. Quiescent satellite cells are activated in response to muscle inju-
ry and/or exercise stimulation leading to muscle recovery [42–44]. In
line with literature, PAX7 expression increased in response to exer-
cise/muscle loading [50–52]. Activated satellite cells, once committed
tomyogenic differentiation becomemyoblasts, which fusewith existing
myoﬁbers [55] through cell–cell interaction involving M-cadherin
[56–58]. Indeed, RL was accompanied by increased expression of M-
cadherin. Remarkably, the biphasic induction of PAX7 and M-cadherin
required GSK-3β, as only a single but more pronounced increase in
their expression was observed in MGSK-3β KO muscle.
Consistent with literature, RL rapidly induced cell proliferation
markers Cyclin D1, PCNA and Ki-67 in reloading muscle [110,131–133],
including a second increase on RL-3, which may signify a secondary
round of myogenic cell proliferation during muscle regeneration. This
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phasic or greater pattern [134,135]. Although stimulating effects of GSK-3
inhibition onmyogenic differentiation andmyotube formationhave been
documented [79,136], it remained to be established whether GSK-3β
ablation affects myoblast proliferation. GSK-3β suppresses Cyclin D1 ex-
pression as reviewed by Takahashi-Yanaga and Sasaguri in cancerous
cells [137], whereas it is required for PCNA content in vascular smooth
muscle cells [138]. This disparity in regulation may reﬂect a GSK-3β de-
pendency that is determined by cellular context. In the reloadingmuscle,
expression patterns of Cyclin D1 and PCNA changed coordinately, and
were impacted similarly by the absence of GSK-3β: GSK-3β ablation
blunted the secondary expression increase of both proliferation markers.
Importantly, the identical GSK-3β-dependency on biphasic increases in
satellite cell activation and proliferation markers during RL supports the
notion that the latter reﬂects dividing myoblasts and no other resident
cell-types. Moreover, since GSK-3β suppression did not directly affect
the expression of proliferation markers but rather promoted myogenic
differentiation of cultured myoblasts [136], the relative suppression of
PCNA and Cyclin D1 expression at day 3 may point at accelerated
myogenesis in the absence of GSK-3β.
Subsequent myogenic differentiation of myoblasts includes in-
creased muscle-speciﬁc gene expression, regulated by the MRFs Myf-
5, MyoD and myogenin [59,60]. Myf-5 expression, suggested to be
involved in satellite cell proliferation [139], was unaffected by RL or
GSK-3β absence. MyoD and myogenin increase during RL, which is in
line with literature [120,132]. Interestingly, early up-regulation of
MyoD and especially myogenin was markedly increased in MGSK-3β
KO compared to WT regenerating muscle, which is consistent with the
stimulation of myogenic differentiation in response to GSK-3 inhibition
observed in a previous in vitro report [65].
Of interest, satellite cell activation and myoblast proliferation
revealed a biphasic response, which preceded the secondary rise in pro-
tein synthesis signaling, i.e. increased phosphorylation of Akt, and S6K
on RL-5, suggesting coordinated control of muscle protein synthesis
and proliferation signaling. This possible second rise of satellite cell ac-
tivation and proliferation markers was absent in MGSK-3β KO muscle,
whereas the initial rise inMGF expression andmyogenic differentiation
markers was clearly more pronounced in MGSK-3β KO muscle. This
may suggest that a second round of satellite cell activation and prolifer-
ation may not be required in MGSK-3β KO muscle as a consequence of
more extensive myogenic differentiation of the initially activated and
recruited satellite cells. In agreement with this notion, muscle mass
and myoﬁber CSA increases were not blunted, but even slightly
enhanced in MGSK-3β KO muscle. However, this could have potential
implications for the replenishment of the quiescent satellite cell pool,
considering the requirement for asymmetrical cell division postulated
to confer sustained myogenic potential of the skeletal muscle in muscle
mass maintenance [140]. In congruence with this idea, the absence of
GSK-3α was recently postulated to accelerate aging of multiple tissues
including the skeletal muscle [141].
All the potentiating effects of GSK-3β deletion on the initial stages of
molecular myogenic differentiation, reloading-induced muscle mass
and myoﬁber CSA recovery were subtle. However, this does not rule
out further attention for GSK-3 as a nexus in skeletal muscle mass
plasticity. We previously reported that reloading of disuse-induced
atrophied soleus muscle mass recovery is accompanied by increased
inactivating GSK-3β phosphorylation [78]. Under physiological healthy
conditions reloading may suppress GSK-3 activity levels sufﬁciently to
accommodate muscle recovery. However, whether such reduction
in GSK-3 activity is required for efﬁcient recovery remains to be ad-
dressed; especially as aberrant GSK-3 regulation has been associated
with impaired muscle mass plasticity [142–144]. Moreover, putative
beneﬁcial effects ofmodulatingGSK-3 activitymay vary between differ-
ent triggers of muscle atrophy, and subsequent recovery conditions. To
illustrate this, the systemic delivery of a GSK-3β inhibitor was recently
found to attenuate muscle atrophy in a model of chronic pulmonaryinﬂammation, and improve cytokine- or glucocorticoid-induced inhibi-
tion of myogenic differentiation [145].
In conclusion, GSK-3β deletion potentiates the initiation of the
molecular response underlying myonuclear accretion, resulting in en-
hanced muscle mass and ﬁber CSA gain. This study therefore suggests
that GSK-3β speciﬁc, non-redundant functions with GSK-3α, or total
GSK-3 (activity) levels suppress muscle regeneration during the recov-
ery of disuse-atrophy.
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